The document discusses preparing for and handling an FDA inspection at a facility. It covers the FDA's authority to inspect facilities and outlines the different types of inspections including routine, concise, follow-up, special, and quality systems reviews. It also discusses the inspection process, providing details on the frequency, duration, and whether inspections are announced or unannounced. Tips are provided on how to prepare for an inspection, what to do during an inspection, and what information is allowed and not allowed to be shared with FDA inspectors.
How to prepare and handle a FDA Inspection. When the FDA conducts an audit of your company, you need to be prepared. This presentation shows you what to do when your are faced with a FDA Inspection. For more information go to http://compliance-insight.com/fda-483-warning-letters/fda-483-inspection/
In this presentation from Validation Week Europe, Karen Ginsbury discusses the rigors, preparations, strategies, and the do's and the don't of the FDA Inspection process.
This article will provide clarity on all below mentioned points,
FDA Audit - The Do and Don't List
How to Prepare for a FDA Inspection
FDA Basics for Industry > What should I expect during an inspection?
What to Expect When Being Inspected - FDA
FDA Inspections: Face the Challenge Through Proactive PreparationTips to Help You Prepare for an FDA Inspection
Inspection Readiness
US food and drug administration Indian site inspections: An experience
Dealing with a "difficult" FDA investigator
Strategies For Managing FDA Inspection Compliance Risks
Dear Readers,
Through PRES we are trying to connect with the Global Pharma community. Where we discussed, share and explore lots of pharmaceutical hot topics. Being a Pharma professional it is very difficult to get time for own to do something different other than routine responsibilities. Hope you all paraprofessionals are agreed with my views.
That’s you, the readers and followers of my blog, who always encouraged me a lot to do something different than my routine schedule. All the information are easily available web media, I am just trying too collate all those information in a single article.
I have collated the information’s broadly from the Pharmacompliancemonitor, FDA and other regulatory website for this article.
Once again I would like to thanks my readers, followers and seniors, who has encourage me a lot.
PRES Mission
To develop scientifically sound, practical, technical information and resources to advance science and regulation for the pharmaceutical industry
PRES Vision
To be the foremost global provider of science, technology, and regulatory information and education for the pharmaceutical community
This presentation is aimed at providing information on automation in the GLP practices in the pharmaceutical industry.
-Standard Operating Procedures.
-Documentation in GALP.
-Logs and Related Forms.
How to prepare and handle a FDA Inspection. When the FDA conducts an audit of your company, you need to be prepared. This presentation shows you what to do when your are faced with a FDA Inspection. For more information go to http://compliance-insight.com/fda-483-warning-letters/fda-483-inspection/
In this presentation from Validation Week Europe, Karen Ginsbury discusses the rigors, preparations, strategies, and the do's and the don't of the FDA Inspection process.
This article will provide clarity on all below mentioned points,
FDA Audit - The Do and Don't List
How to Prepare for a FDA Inspection
FDA Basics for Industry > What should I expect during an inspection?
What to Expect When Being Inspected - FDA
FDA Inspections: Face the Challenge Through Proactive PreparationTips to Help You Prepare for an FDA Inspection
Inspection Readiness
US food and drug administration Indian site inspections: An experience
Dealing with a "difficult" FDA investigator
Strategies For Managing FDA Inspection Compliance Risks
Dear Readers,
Through PRES we are trying to connect with the Global Pharma community. Where we discussed, share and explore lots of pharmaceutical hot topics. Being a Pharma professional it is very difficult to get time for own to do something different other than routine responsibilities. Hope you all paraprofessionals are agreed with my views.
That’s you, the readers and followers of my blog, who always encouraged me a lot to do something different than my routine schedule. All the information are easily available web media, I am just trying too collate all those information in a single article.
I have collated the information’s broadly from the Pharmacompliancemonitor, FDA and other regulatory website for this article.
Once again I would like to thanks my readers, followers and seniors, who has encourage me a lot.
PRES Mission
To develop scientifically sound, practical, technical information and resources to advance science and regulation for the pharmaceutical industry
PRES Vision
To be the foremost global provider of science, technology, and regulatory information and education for the pharmaceutical community
This presentation is aimed at providing information on automation in the GLP practices in the pharmaceutical industry.
-Standard Operating Procedures.
-Documentation in GALP.
-Logs and Related Forms.
This ppt consists of types of FDA inspection, and how to prepare for FDA inspection of pharmaceutical mfg site, and what to do before FDA inspection, During FDA inspection, and after FDA inspection.
Preparing For An FDA Inspection - Employee Reviewguest22cdb3
An employee review training session adapted from presentations by former Food and Drug Administration investigators. The presentation includes a team competition based on a popular game show.
How to Prepare for an FDA Inspection and Respond to FDA 483's / Warning LettersGreenlight Guru
How long has it been since your last FDA inspection?
You know FDA is technically mandated to inspect any company with class II or class III products every two years (and inspections have been on the rise particularly for foreign / outside the US firms).
If FDA called tomorrow to announce their plans to visit your facility next week would you be prepared?
Even the most prepared companies still often find themselves receiving 483 observations.
Then you must act swiftly and effectively to avoid that observation escalating to a warning letter.
But what exactly do you do?
How do you respond to FDA 483 observations and/or warning letters?
greenlight.guru founder and VP QA/RA, Jon Speer, has been through his fair share of FDA inspections over the course of his 17+ year career in the medical device industry and has helped many of companies respond to 483 observations and warning letters along the way.
In this free, 60 minutes webinar, Jon will be sharing his most effective tips on how to avoid 483’s and warning letters in the first place along with a step-by-step guide to responding the them if you do happen to receive either.
(You can view the full webinar here: http://www.greenlight.guru/webinar/fda-483-warning-letter-response)
Specifically you'll learn:
What you should be doing to always be prepared for an FDA inspection
How to help prep your team before an FDA inspection
The top 7 reasons FDA issued medical device companies 483 observations and warning letters in FY2015
Tips you can implement today to mitigate your risk of getting 483’s and warning letters
What you need to do before responding to a 483 to minimize the damage (and avoid the common pitfalls)
Best practices for responding to FDA 483 and warning letter (including a free response template)
The differences in responding to a 483 observation vs. a warning letter
What to expect from FDA after submitting your response
A guide for how to survive a FDA Warning letter. So you got at FDA 483 and now you have a FDA Warning Letter, learn how to survive the storm. For more information go to http://compliance-insight.com/fda-483-warning-letters/
This presentation contain introduction to Good Distribution Practices Guideline. and Legal GDP requirements put worldwide.
Good distribution practice (GDP) describes the minimum standards that a wholesale distributor must meet to ensure that the quality and integrity of medicines is maintained throughout the supply chain
Each participant in the distribution chain must agree by the relevant requirements in order to retain the original quality of pharmaceutical products.
Each activity in the distribution of pharmaceutical products shall be carried out according to the principles of Good Distribution Practices (GDP) as applicable.
The risks involved are likely to be of a nature comparable to those that are present in the industrial environment, such as mix-ups, adulteration, contamination, cross-contamination, and spurious.
The guideline addresses
Personnel
Quality System
Premises Warehousing and Storage
Documentation
Traceability
Complaints and Returns
Transportation
Current Good Manufacturing Practices: Drug and Biologics Rachel Hamilton
ACI’s FDA Boot Camp has been designed to give products or patent litigators, as well as patent prosecutors, industry in-house counsel, and life sciences investment and securities experts, a strong working knowledge of core FDA competencies.
This ppt consists of types of FDA inspection, and how to prepare for FDA inspection of pharmaceutical mfg site, and what to do before FDA inspection, During FDA inspection, and after FDA inspection.
Preparing For An FDA Inspection - Employee Reviewguest22cdb3
An employee review training session adapted from presentations by former Food and Drug Administration investigators. The presentation includes a team competition based on a popular game show.
How to Prepare for an FDA Inspection and Respond to FDA 483's / Warning LettersGreenlight Guru
How long has it been since your last FDA inspection?
You know FDA is technically mandated to inspect any company with class II or class III products every two years (and inspections have been on the rise particularly for foreign / outside the US firms).
If FDA called tomorrow to announce their plans to visit your facility next week would you be prepared?
Even the most prepared companies still often find themselves receiving 483 observations.
Then you must act swiftly and effectively to avoid that observation escalating to a warning letter.
But what exactly do you do?
How do you respond to FDA 483 observations and/or warning letters?
greenlight.guru founder and VP QA/RA, Jon Speer, has been through his fair share of FDA inspections over the course of his 17+ year career in the medical device industry and has helped many of companies respond to 483 observations and warning letters along the way.
In this free, 60 minutes webinar, Jon will be sharing his most effective tips on how to avoid 483’s and warning letters in the first place along with a step-by-step guide to responding the them if you do happen to receive either.
(You can view the full webinar here: http://www.greenlight.guru/webinar/fda-483-warning-letter-response)
Specifically you'll learn:
What you should be doing to always be prepared for an FDA inspection
How to help prep your team before an FDA inspection
The top 7 reasons FDA issued medical device companies 483 observations and warning letters in FY2015
Tips you can implement today to mitigate your risk of getting 483’s and warning letters
What you need to do before responding to a 483 to minimize the damage (and avoid the common pitfalls)
Best practices for responding to FDA 483 and warning letter (including a free response template)
The differences in responding to a 483 observation vs. a warning letter
What to expect from FDA after submitting your response
A guide for how to survive a FDA Warning letter. So you got at FDA 483 and now you have a FDA Warning Letter, learn how to survive the storm. For more information go to http://compliance-insight.com/fda-483-warning-letters/
This presentation contain introduction to Good Distribution Practices Guideline. and Legal GDP requirements put worldwide.
Good distribution practice (GDP) describes the minimum standards that a wholesale distributor must meet to ensure that the quality and integrity of medicines is maintained throughout the supply chain
Each participant in the distribution chain must agree by the relevant requirements in order to retain the original quality of pharmaceutical products.
Each activity in the distribution of pharmaceutical products shall be carried out according to the principles of Good Distribution Practices (GDP) as applicable.
The risks involved are likely to be of a nature comparable to those that are present in the industrial environment, such as mix-ups, adulteration, contamination, cross-contamination, and spurious.
The guideline addresses
Personnel
Quality System
Premises Warehousing and Storage
Documentation
Traceability
Complaints and Returns
Transportation
Current Good Manufacturing Practices: Drug and Biologics Rachel Hamilton
ACI’s FDA Boot Camp has been designed to give products or patent litigators, as well as patent prosecutors, industry in-house counsel, and life sciences investment and securities experts, a strong working knowledge of core FDA competencies.
Regulatory Highlights and Drug Development in ChinaMedpace
Regulatory Highlights and Drug Development in China was presented at the 5th China Clinical Trials Outsourcing Congress March 4-5, 2013 by Xiaoxiong (Jim) Wei, MD, PhD, Medical Director at Medpace.
Indian GMP Certification & WHO GMP CertificationVishal Shelke
Indian GMP Certification & WHO GMP Certification by Mr. Vishal Shelke
https://youtube.com/vishalshelke99
https://instagram.com/vishal_stagram
Sub :- Drug Regulatory Affairs
M.Pharm Sem II
Savitribai Phule Pune University
FDA Inspections are Different from ISO Audits, So Don't Treat Them the Same -...April Bright
ISO audits and FDA inspections differ logistically, and should be approached in different manners. This presentation will explain the real-time differences between the two and, most importantly, give you strategies for preparation, behavioral tips for success during and after the assessments and recommendations for responding to the Registrar or FDA if deficiencies were discovered.
Ian brings 16 years of experience in the Biotech/Pharmaceutical Industry in Quality Assurance and Quality Control. He has extensive knowledge of all of the applicable regulatory requirements.
My last projects as an independent contractor were with SHIRE, LONZA and NOVARTIS. I conducted Product Investigations from Inoculations of Media to Manufacturing projects which included from line clearance issues to inclusions of foreign material. Also, Inspection of all product packaging to determine a non-negative product impact.
Trust, but Verify - Tips & Tools for FSMA's Foreign Supplier VerificationTraceGains
The FDA’s Food Safety Modernization Act (FSMA) rule on Foreign Supplier Verification Programs (FSVP) for Importers of Food for Humans and Animals is now final, and compliance dates for some businesses begin in 18 months. To help the food supply chain prepare, TraceGains’ will zero-in on the FSVP in its upcoming webinar: “Trust, but Verify – Tips and Tools for Foreign Supplier Verification (FSV).”
TraceGains will host FDA attorney Marc Sanchez as its guest speaker for the webinar. The session is designed to give an overview of the key provisions and tips and tools you can use to simplify compliance with the new requirements and establish a world-class FSVP.
Specifically, the webinar will cover:
Examining your current supplier program and how to identify gaps in hazard analysis;
What the FDA says about electronic record-keeping for FSV;
What involvement is expected from the executive and management level;
Third-party verification of foreign suppliers;
Risk management best practices for FSV; and,
Tips & tools to simplify compliance with FSV.
Speaker: Anne Tomalin, BA, BSc, RAC (US, CAN & EU), President of CanReg Inc.
Topics Addressed
* Planning ahead to add credibility and value with your partners, investors and outside experts
* What is the landscape of various filings for a drug, a medical device or a diagnostic device?
* Developing a multi-disciplinary project team to manage your regulatory strategy:
o Different strategies for different products
o How to formulate a sound path to drug development decision-making
* What is needed for approval of a medical device
* The preclinical studies required for an IND filing
* The multiple components of the actual IND submission
* Management and communication between the teams assembling the IND
o When to outsource and bring in consultants
* Interacting with the regulatory authority
Download an audio file of this presentation at:
http://www.marsdd.com/bioent/jan15
In this presentation from, Janeen Santorosa discusses the best practices for harmonization of GMP auditing, domestic and international regulations for supplier auditing, integration of risk-based practices, and supplier audit practice tools.
In this presentation from IVT's 4th Annual Validation Week EU, Paul Pluta, discussed the differences between the traditional approach to cleaning validation and the lifecycle approach, applicable regulatory guidance, current industry trends, the necessary phases of the lifecycle approach (design and definition, cycle development, validation, and implementation), how to continously monitor the process, change control, and common obstacles to compliance.
This session from the Institute of Validation Technology's 14th Annual CSV Conference looks at B. Braun’s journey in moving from an in-house validated training tracking system to learning management in the cloud.
In this session from the Institute of Validation Technology's Validation Week Europe, Kurtis Epp and John Kandl discuss how to implement QbD to all three stages of process validation.
This presentation from the Institute of Validation Technology's first annual Validation and cGMP Compliance Week Singapore discusses the obstacles to quality such, the key components to improve quality, and the tools for strategic teamwork.
This session from the Institute of Validation Technology's Contamination and Control Week discusses regulatory expectations and industry drivers for aseptic cleaning and environmental monitoring, regulatory expectations for cleanrooms, and current FDA and EU expectations during inspection of sterile and aseptic operations.
In this presentation from the Institute of Validation Technology's Life Sciences Aseptic Processing, Kim Van Antwerpen discusses collecting environmental data, methods for trending, and interpreting and sharing environmental monitoring data.
Regulatory inspections have had a significant impact on the number of drug shortages and companies facing adverse regulatory actions.
Review of the inspection trends can be useful in assessing the regulatory status of your own company and help aid in the preparation for upcoming inspections. This session from IVT's Contamination and Control Week provides an in-depth, practical look at some of the recent Warning Letters and discusses current trends.
The Validation Master Plan is a a valuable opportunity to provide an overview of your company’s validation process, including organization structure, content, and planning.
Regulatory guidelines on stability testing are mainly designed to address studies that will be applied to support NDAs. However, in any pharmaceutical development program, a number of other stability studies are also required, for example, to help select appropriate formulations and to support regulatory applications for clinical programs. This session from the Institute of Validation Technology's Stability Programs Forum outlines a number of examples of early development stability studies.
This presentation from IVT's 4th Annual reviews what to do when you have an exception, critical vs. non-critical exceptions, and learning how to prevent exceptions.
This presentation from IVT's 4th Annual Validation Week Europe provided a thorough explanation of developing a gap analysis, areas in validation that are issues of concern, and FDA expectations of a manufacturer's gap analysis.
This workshop examines the approach to Continued Process Verification and demonstrating that your product and process are operating in a state of control and continue to do so over the life of the product. Without any prior coordination, the theme was elaborated by the afternoon speakers once the conference itself was underway. The concept of “step up step down” for adjusting the level of product scrutiny both for process parameters monitoring and for sampling and testing quality attributes was explored and developed.
In this presentation from IVT's GMP Week, Journal of Validation Technology Editor-in-Chief, Paul Pluta, Ph.D., asks "can compliance be improved by using quality by design [QbD] concepts?" Pluta discussed the QbD application, development of validation master plans, and the lifecycle approach to process validation. Furthermore, he discusses how to incorporate these essential parts of the validation process to implement effective, and efficient, compliance by design into the quality system.
This presentation from IVT's 2nd Annual Validation Week Canada covers the 2011 FDA Process validation and the subsequent statistical processes. Statistics in process validation is introduced as well as the integration with six sigma and solutions to common mistakes.
A comprehensive presentation on GMP systems and integration. This includes validations, vendor qualification, preventative maintenance, audits, CAPA, and utilization of system results.
This presentation from IVT Network's Method Validation Conference covers required and suggested regulations and guidances for biological process specifications. It also covers dosage form considerations and specifications for other components.
8. Types of GMP Inspection
Objective of the inspection
! Routine inspection
! Concise inspection
! Follow-up inspection
! Special inspection
! Quality systems review
8
9. Types of GMP Inspection
Routine Inspection
! Full inspection of all components of GMP
! Newly established manufacturer
! Renewal of a license
! Changes:
new product or product lines
modifications to manufacturing methods
key personnel, premises or equipment
! History of non-compliance with GMP
! Not inspected in the last 3-5 years
9
10. Types of GMP Inspection
Concise Inspection
! Consistent record of compliance with GMP
! Focus on limited number of GMP requirements
selected as indicators
! Identify significant changes
! Indicate attitude towards GMP
! Non-compliance
should trigger comprehensive inspection
10
11. Types of GMP Inspection
Follow-up Inspection
! Reassessment or re-inspection
! Monitor result of corrective actions
! 6 weeks to 6 months after initial inspection
nature of defects
work undertaken
! Specific GMP requirements
not observed
– not adequately implemented
11
12. Types of GMP Inspection
Special Inspection
! Spot check focusing on
one product, a group of related products
specific operations, e.g. mixing, labelling
! Complaints or recalls
! Adverse drug reactions
! Marketing approval or export certificate
! Information or investigation
specific information
advice on regulatory requirements
12
13. Types of GMP Inspection
Quality Systems Review
! Assess the quality assurance (QA) system
! Description of the QA system (e.g. manual)
! Policy and standards to be observed
! Management structure
implementation
! Procedures
quality standards set for products
correctly defined manufacturing processes
records kept
QC and QA functions are performed
13
14. Types of GMP Inspection
Frequency of Inspections
! Depends on type of inspection
! Inspectorate resources (e.g. workload, number of inspectors)
! New facilities - before licensed
! All companies - regular schedule
ideally annual
! Large companies
several visits over a period, e.g. 5 years
validity of manufacturing license or GMP certificate
14
15. Types of GMP Inspection
Duration of Inspections
! Depends on type of inspection
! Inspectorate resources (e.g. workload, number of inspectors)
! Size of the company
! Purpose of the visit
! Days to weeks
! Number of inspectors
including specialist support
15
16. Types of GMP Inspection
Announced and unannounced inspections
! Depends on type of inspection
! Announced
comprehensive inspection
! Unannounced
routine inspection (depending on country policy)
concise inspection
follow-up inspection
special inspection
16
18. Centers and Offices
! Office of the Commissioner Organization
! Center for Biologics Evaluation and Research Organization
! Center for Devices and Radiological Health Organization.
! Center for Drug Evaluation and Research Organization
! Center for Food Safety and Applied Nutrition Organization.
! Center for Tobacco Products Organization
! Center for Veterinary Medicine Organization
! National Center for Toxicological Research Organization
! Office of Regulatory Affairs Organization.
18
19. Office of Regulatory Affairs (ORA)
http://www.fda.gov/ora/
Headquarters:
Rockville, MD
Regional Office:
Philadelphia, PA
District Office:
Detroit, MI
19
20. FDA Field Investigators
! Conduct inspections to enforce the
Food, Drug and Cosmetic Act
! Train themselves in “evidence
collection”
! “If it’s not documented, it didn’t happen.”
20
21. FDA Inspection Process
FDA Office Site Location
1. Select Site 4. Arrive (482)
2. Contact Site 5. Review Records
3. Schedule Site 6. Interview Staff
9. Write Report (EIR) 7. Present Findings
10. Classify Inspection 8. Depart (483)
21
29. ! While there are several types of audits with several
different types of focus’:
! Annual Flu Vaccine
! Bi-annual audit
! Pre Approval Inspection (PAI)
! For Cause Audit
! Etc
! We will now discuss preparing for a PAI inspection –
however many of the points apply to any type of FDA
audit.
29
43. INSPECTION DOs
ü DO PLAN FOR INSPECTION
ü DO PROVIDE REVELANT DOCUMENTATION
ü DO ANSWER QUESTIONS TO SPECIFIC ACTIVITY
ü DO ESCORT THE INSPECTOR
ü DO TAKE NOTES
ü DO COPY DOCUMENTS REMOVED
ü DO STAMP THE REMOVE DOCUMENTS
ü DO COOPERATE WITH THE FDA
ü BE POLITE BUT FIRM WITH YOUR RIGHTS
43
44. REFUSE FDA ACCESS
Ø FINANCIAL DATA
Ø SALES VALUES
Ø PRICING
Ø PERSONNEL DATA
Ø MANAGEMENT REVIEWS
Ø INTERNAL AUDITS
Ø SUPPLIER AUDITS
44
45. INSPECTION DON’Ts
ü DON’T OVER SPEAK OR SAY IT’S IMPOSSIBLE
ü DON’T ALLOW RECORDINGS
ü DON’T SIGN AFFIDAVITS
ü DON’T ALLOW ACCESS TO FILES
ü DON’T GUESS AT AN ANSWER
ü DON’T ANSWER “WHAT IF ?”
ü DON’T ENGAGE IN ARGUMENT
45